Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Pfizer
Tomsk National Research Medical Center of the Russian Academy of Sciences
University Hospital Heidelberg
City of Hope Medical Center
Amgen
Replimune Inc.
M.D. Anderson Cancer Center
Pfizer
Ohio State University Comprehensive Cancer Center
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
Roswell Park Cancer Institute
Seagen Inc.
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
AgonOx, Inc.
Novartis
TILT Biotherapeutics Ltd.
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
Integro Theranostics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Massachusetts General Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, Irvine
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
HUYABIO International, LLC.
City of Hope Medical Center
DeuterOncology
BeiGene
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Compugen Ltd
National Cancer Institute (NCI)
Checkpoint Therapeutics, Inc.
Jonsson Comprehensive Cancer Center
Revolution Medicines, Inc.
R-Pharm
AO GENERIUM